Radiopharm Theranostics Presents Interim Analysis from Phase 2b Imaging Study of RAD101 in Suspected Recurrent Brain Metastases Following Radiotherapy at the Society for Neuro-Oncology Annual Meeting
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Radiopharm Theranostics (Nasdaq: RADX) presented interim Phase 2b RAD101 imaging results in patients with suspected recurrent brain metastases following radiotherapy.
The 32-participant study reported 93.5% patient-level agreement between RAD101 PET/CT and contrast-enhanced MRI for all-lesion detection, its primary endpoint. Preliminary sensitivity—the ability to identify disease against a reference standard—was 85.7% among 16 evaluable participants. No serious treatment-emergent adverse events or clinically significant laboratory or ECG abnormalities were observed.
The company plans final analyses, including specificity and complete diagnostic follow-up, in Q1 2027. It recently announced FDA alignment on a single multicenter Phase 3 imaging trial. RAD101 has FDA Fast Track designation, and Siemens Healthineers will manufacture and distribute doses for the upcoming U.S. Phase 3 trial.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointRAD101 achieved 93.5% patient-level agreement with contrast-enhanced MRI for all-lesion detection, the primary endpoint.
- Moderate pointFDA alignment covers a single multicenter Phase 3 imaging trial for indeterminate brain metastases following radiotherapy.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Siemens Healthineers will manufacture and distribute RAD101 doses for the upcoming U.S. Phase 3 registrational trial.
- Minor pointPreliminary sensitivity was 85.7% among 16 participants evaluable against the reference standard at interim analysis.
- Minor pointSafety findings included no serious treatment-emergent adverse events or clinically significant laboratory or ECG abnormalities in 32 participants.
2 minor points
- Minor pointRAD101 received FDA Fast Track designation to distinguish recurrent disease from treatment effects in brain metastases, including leptomeningeal disease.
- Minor point. Forward-looking: it has not happened yet and may not happen.Radiopharm plans Q1 2027 reporting of final analyses, including specificity and complete diagnostic follow-up.
Negative
- Minor pointDiagnostic accuracy remains interim; only 16 of 32 participants were evaluable against the reference standard.
Key Figures
- Patient-level agreement
- 93.5%
- 18F-RAD101 PET/CT versus contrast-enhanced MRI; all-lesion detection
- Sensitivity
- 85.7%
- Interim analysis against the reference standard
- Evaluable participants
- 16 participants
- Evaluable against the reference standard at interim analysis
- Participants dosed
- 32 participants
- Phase 2b imaging study
- Serious treatment-emergent adverse events
- None observed
- Among the 32 participants dosed
- Final diagnostic analyses
- Q1 2027
- Planned reporting of specificity and complete diagnostic performance on follow-up
Previous Clinical trial Reports
-
FDA alignment set one pivotal Phase 3 design, approximately 280 patients, and sensitivity/specificity co-primary endpoints.
-
Earlier interim findings reported 93% concordance and 86% sensitivity in the same RAD101 Phase 2b study.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
pet/ct technical
histopathology medical
ecg medical
fast track designation regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Concordance between 18F-RAD101 PET and contrast-enhanced MRI (
Favourable safety profile with no serious treatment-emergent adverse events observed in any of the 32 participants dosed
Final analyses including specificity and complete diagnostic performance on follow-up planned to be reported in Q1 2027
Recently announced alignment with the U.S. FDA for a single, multicenter Phase 3 imaging trial evaluating RAD101 in patients with indeterminate brain metastases following radiotherapy
SYDNEY, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that data from the Phase 2b imaging study of RAD101 in suspected recurrent brain metastases following radiotherapy were presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting, which took place from November 12-15, 2026 in Philadelphia, PA.
“We were honored to present these encouraging interim Phase 2b results at SNO before an audience of neuro-oncology experts who confront the challenge of distinguishing recurrent disease from treatment-related effects on a daily basis,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. “For clinicians caring for patients with brain metastases, uncertainty in imaging can have profound implications for treatment decisions, making the need for more accurate diagnostic tools increasingly urgent. We believe the high concordance observed between RAD101 PET/CT and MRI, together with encouraging preliminary sensitivity data and a favorable safety profile, further supports RAD101’s potential to address this critical unmet need. Following our recent alignment with the U.S. FDA on a pivotal Phase 3 imaging study, we remain focused on advancing RAD101 toward a prospective regulatory submission and are actively engaging with potential strategic partners. We look forward to reporting additional diagnostics accuracy analyses as we continue to build the evidence supporting RAD101’s differentiated value.”
The Phase 2b, open-label, single-dose, single-arm, multicenter imaging study enrolled 32 participants who had suspected recurrence of previously irradiated brain metastases.
The primary endpoint was concordance with MRI, which had high patient-level agreement between 18F-RAD101 PET/CT and contrast-enhanced MRI at
RAD101 has received FDA Fast Track Designation to distinguish between recurrent disease and treatment effect of brain metastases originating from solid tumors of different origin including leptomeningeal disease. The company has also announced a partnership with Siemens Healthineers, who will manufacture and distribute doses of 18F-labeled RAD101 to support the upcoming Phase 3 registrational trial in the U.S.
In the U.S. alone, there are more than 300,000 patients diagnosed annually with brain metastases. The incidence of Intracranial Metastatic Disease (IMD) continues to increase, in part, due to improvements in systemic therapy resulting in a more durable control of the tumors outside of the central nervous system. Contrast-enhanced Magnetic Resonance Imaging (CE-MRI) is the preferred method for imaging IMD, but has limitations, particularly in follow-up surveillance scans to optimise patient care.1
About RAD101
RAD101 is an ¹⁸F-labelled fatty acid analogue that images FASN-associated fatty acid metabolism in brain metastases. (FASN) is a multi-enzyme protein that catalyses de novo fatty acid synthesis and is overexpressed in brain metastases from solid tumors. Targeting FASN activity may allow for the more accurate detection of cancer cells in the CNS, representing a clinically relevant method for the imaging of brain metastases. Positive data from the Imperial College London’s Phase 2a imaging trial of 18F-RAD101 in patients with brain metastases (both SRS pre-treated and treatment naïve patients) showed significant tumor uptake that was independent from the tumor of origin. The study further indicated that PET-MRI may provide non-invasive prediction of overall survival, warranting larger studies.
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and five Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com
Authorised on behalf of the Radiopharm Theranostics board of directors by Chairman Paul Hopper.
For more information:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Anne Marie Fields
Precision AQ (Formerly Stern IR)
E: annemarie.fields@precisionaq.com
Media
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
________________________________
1 A hybrid [18F]fluoropivalate PET-multiparametric MRI to detect and characterise brain tumour metastases based on a permissive environment for monocarboxylate transport | European Journal of Nuclear Medicine and Molecular Imaging
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Radiopharm Theranostics' RAD101 Phase 2b interim study show?
RAD101 showed 93.5% patient-level agreement with contrast-enhanced MRI for all-lesion detection and preliminary sensitivity of 85.7% among 16 participants evaluable against the reference standard. No serious treatment-emergent adverse events were observed among the 32 participants dosed.
When will Radiopharm report final RAD101 Phase 2b diagnostic results?
Radiopharm plans to report final analyses, including specificity and complete diagnostic follow-up, in Q1 2027.
How was Radiopharm's RAD101 Phase 2b study designed?
The study was open-label, single-dose, single-arm and multicenter, enrolling 32 participants with suspected recurrence of previously irradiated brain metastases. The reference standard used to evaluate sensitivity was histopathology, meaning tissue examination, or longitudinal MRI follow-up.